---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-232621"
form_type: "8-K"
ticker: "CNMD"
cik: "0000816956"
company_name: "CONMED Corp"
filed_at: "2024-10-04T23:59:59+00:00"
generated_at: "2026-05-30T21:00:17.438283+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CONMED prelim Q3 rev $315-318M; adj EPS growth to exceed 9-11% guide

## Summary
- Revenue expected $315M-$318M for Q3 2024 (preliminary).
- Adjusted diluted EPS growth exceeds previously guided 9%-11% range.
- Full Q3 results to be reported Oct 30, 2024 after market close.
- Data is preliminary; may change upon completion of financial close.

## SEC filing metadata
- accession: 0001193125-24-232621
- form_type: 8-K
- ticker: CNMD
- cik: 0000816956
- company_name: CONMED Corp
- filed_at: 2024-10-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/816956/000119312524232621/0001193125-24-232621-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/816956/000119312524232621/d117527d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-232621
- JSON: https://secwatch.observer/filing/0001193125-24-232621.json
- Plain text: https://secwatch.observer/filing/0001193125-24-232621.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.